Breaking News

Memel Biotech Launches Advanced Therapy Development & Manufacturing Service

Will target partnerships with both emerging and established biotech companies looking to enter the advanced therapy space.

Memel Biotech has launched a fully integrated advanced therapy development and manufacturing service from its facility located at the Baltic seaport of Klaipeda, Lithuania.
 
Memel will target partnerships with both emerging and established biotech companies looking to enter the advanced therapy space. Operating from a new GMP facility, Memel will offer a seamless discovery-to-delivery service for all three classes of advanced therapies – cell, gene, and tissue engineered.
 
Memel’s manufacturing range includes Mesenchymal Stem Cells (MSCs), Induced Pluripotent Stem Cells (iPSCs), Extracellular Vesicles (EVs), Immune cells (NK, DC) and gene modified cells, including CAR-T cells.
 
CEO Agnė Vaitkevičienė explains the reasoning behind Memel’s foundation: “Advanced therapies have enormous potential to make life changing impacts on patients, but there is no escaping the fact that they are complex and challenging to manufacture and deliver. Based on our previous experience in the sector, we believe Memel has the portfolio of services and skills to meet the challenges companies that are aiming to make a difference face – from initial formulation to scale-up – whilst conforming to the still emerging regulatory framework. In addition to European clients, our location also offers an ideal EU entry point to US and ROW companies.”
 
Cureline Group President Olga Potapova adds: “Memel is a natural extension of the Group’s portfolio. We have closely followed the development of the advanced therapies sector over the last decade in particular. Rather than try to repurpose any existing CDMO we believe the time is right to create a truly specialized partner who can take an active role in helping customers achieve their missions to bring these exciting new treatments to patients. Lithuania with its highly skilled workforce, supportive environment, stability and EU membership is also an ideal location.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters